瀾起科技(688008.SH):目前主流的內存廠商已相繼推出CXL內存擴展產品
格隆匯9月5日丨瀾起科技(688008.SH)在投資者關係活動上表示,首先大規模應用的將是內存擴展,目前主流的內存廠商已相繼推出CXL內存擴展產品。公司在去年5月全球首發MXC芯片後,已與全球多家頂級雲計算廠商及內存龍頭企業開展合作。今年5月,三星電子推出其首款支持CXL2.0的128GBDRAM,並表示將於今年量產,加速下一代存儲器解決方案的商用化,公司的MXC芯片被用於該解決方案,是其中的核心控制芯片。另一方面的應用是內存池化,其作用更多是提升整個數據中心的經濟效益,比如平衡服務器內存波峯波谷的需求。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.